vs
Side-by-side financial comparison of ANI PHARMACEUTICALS INC (ANIP) and Claritev Corp (CTEV). Click either name above to swap in a different company.
ANI PHARMACEUTICALS INC is the larger business by last-quarter revenue ($247.1M vs $246.6M, roughly 1.0× Claritev Corp). ANI PHARMACEUTICALS INC runs the higher net margin — 11.1% vs -32.7%, a 43.8% gap on every dollar of revenue. On growth, ANI PHARMACEUTICALS INC posted the faster year-over-year revenue change (29.6% vs 6.2%). Claritev Corp produced more free cash flow last quarter ($36.4M vs $29.1M). Over the past eight quarters, ANI PHARMACEUTICALS INC's revenue compounded faster (34.1% CAGR vs 2.5%).
ANI Pharmaceuticals Inc is a U.S.-based specialty pharmaceutical firm that develops, manufactures and sells generic and branded prescription drugs. Its key segments cover dermatology, oncology, CNS therapies and anti-infectives, primarily serving U.S. healthcare providers, retail pharmacies and institutional medical clients.
ANIP vs CTEV — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $247.1M | $246.6M |
| Net Profit | $27.5M | $-80.6M |
| Gross Margin | — | — |
| Operating Margin | 14.1% | -3.1% |
| Net Margin | 11.1% | -32.7% |
| Revenue YoY | 29.6% | 6.2% |
| Net Profit YoY | 367.5% | 41.6% |
| EPS (diluted) | $1.14 | $-4.88 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $247.1M | $246.6M | ||
| Q3 25 | $227.8M | $246.0M | ||
| Q2 25 | $211.4M | $241.6M | ||
| Q1 25 | $197.1M | $231.3M | ||
| Q4 24 | $190.6M | $232.1M | ||
| Q3 24 | $148.3M | $230.5M | ||
| Q2 24 | $138.0M | $233.5M | ||
| Q1 24 | $137.4M | $234.5M |
| Q4 25 | $27.5M | $-80.6M | ||
| Q3 25 | $26.6M | $-69.8M | ||
| Q2 25 | $8.5M | $-62.6M | ||
| Q1 25 | $15.7M | $-71.3M | ||
| Q4 24 | $-10.3M | $-138.0M | ||
| Q3 24 | $-24.2M | $-391.4M | ||
| Q2 24 | $-2.3M | $-576.7M | ||
| Q1 24 | $18.2M | $-539.7M |
| Q4 25 | 14.1% | -3.1% | ||
| Q3 25 | 15.9% | 4.1% | ||
| Q2 25 | 6.6% | 6.9% | ||
| Q1 25 | 13.3% | 4.2% | ||
| Q4 24 | -2.3% | -17.8% | ||
| Q3 24 | -13.8% | -146.7% | ||
| Q2 24 | 3.7% | -224.4% | ||
| Q1 24 | 14.8% | -207.4% |
| Q4 25 | 11.1% | -32.7% | ||
| Q3 25 | 11.7% | -28.4% | ||
| Q2 25 | 4.0% | -25.9% | ||
| Q1 25 | 8.0% | -30.8% | ||
| Q4 24 | -5.4% | -59.4% | ||
| Q3 24 | -16.3% | -169.8% | ||
| Q2 24 | -1.7% | -247.0% | ||
| Q1 24 | 13.2% | -230.1% |
| Q4 25 | $1.14 | $-4.88 | ||
| Q3 25 | $1.13 | $-4.23 | ||
| Q2 25 | $0.36 | $-3.81 | ||
| Q1 25 | $0.69 | $-4.38 | ||
| Q4 24 | $-0.45 | $-8.49 | ||
| Q3 24 | $-1.27 | $-24.25 | ||
| Q2 24 | $-0.14 | $-35.78 | ||
| Q1 24 | $0.82 | $-33.40 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $285.6M | $16.8M |
| Total DebtLower is stronger | — | $4.6B |
| Stockholders' EquityBook value | $540.7M | $-173.9M |
| Total Assets | $1.4B | $4.9B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $285.6M | $16.8M | ||
| Q3 25 | $262.6M | $39.2M | ||
| Q2 25 | $217.8M | $56.4M | ||
| Q1 25 | $149.8M | $23.1M | ||
| Q4 24 | $144.9M | $16.8M | ||
| Q3 24 | $145.0M | $86.6M | ||
| Q2 24 | $240.1M | $48.8M | ||
| Q1 24 | $228.6M | $58.7M |
| Q4 25 | — | $4.6B | ||
| Q3 25 | — | $4.5B | ||
| Q2 25 | — | $4.5B | ||
| Q1 25 | — | $4.5B | ||
| Q4 24 | — | $4.5B | ||
| Q3 24 | — | $4.5B | ||
| Q2 24 | — | $4.5B | ||
| Q1 24 | — | $4.5B |
| Q4 25 | $540.7M | $-173.9M | ||
| Q3 25 | $505.8M | $-101.8M | ||
| Q2 25 | $436.8M | $-39.9M | ||
| Q1 25 | $418.6M | $14.8M | ||
| Q4 24 | $403.7M | $84.0M | ||
| Q3 24 | $405.9M | $207.6M | ||
| Q2 24 | $455.8M | $603.4M | ||
| Q1 24 | $452.0M | $1.2B |
| Q4 25 | $1.4B | $4.9B | ||
| Q3 25 | $1.4B | $5.0B | ||
| Q2 25 | $1.3B | $5.1B | ||
| Q1 25 | $1.3B | $5.1B | ||
| Q4 24 | $1.3B | $5.2B | ||
| Q3 24 | $1.3B | $5.3B | ||
| Q2 24 | $920.8M | $5.7B | ||
| Q1 24 | $914.5M | $6.4B |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 304.87× | ||
| Q4 24 | — | 53.67× | ||
| Q3 24 | — | 21.73× | ||
| Q2 24 | — | 7.48× | ||
| Q1 24 | — | 3.85× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $30.4M | $66.3M |
| Free Cash FlowOCF − Capex | $29.1M | $36.4M |
| FCF MarginFCF / Revenue | 11.8% | 14.8% |
| Capex IntensityCapex / Revenue | 0.5% | 12.1% |
| Cash ConversionOCF / Net Profit | 1.10× | — |
| TTM Free Cash FlowTrailing 4 quarters | $171.4M | $-12.3M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $30.4M | $66.3M | ||
| Q3 25 | $44.1M | $19.9M | ||
| Q2 25 | $75.8M | $61.2M | ||
| Q1 25 | $35.0M | $-30.1M | ||
| Q4 24 | $15.9M | $-33.4M | ||
| Q3 24 | $12.5M | $72.8M | ||
| Q2 24 | $17.4M | $18.5M | ||
| Q1 24 | $18.3M | $49.7M |
| Q4 25 | $29.1M | $36.4M | ||
| Q3 25 | $38.0M | $-16.3M | ||
| Q2 25 | $71.8M | $36.6M | ||
| Q1 25 | $32.5M | $-68.9M | ||
| Q4 24 | $13.5M | $-63.8M | ||
| Q3 24 | $7.7M | $41.1M | ||
| Q2 24 | $13.0M | $-7.0M | ||
| Q1 24 | $13.7M | $19.2M |
| Q4 25 | 11.8% | 14.8% | ||
| Q3 25 | 16.7% | -6.6% | ||
| Q2 25 | 34.0% | 15.2% | ||
| Q1 25 | 16.5% | -29.8% | ||
| Q4 24 | 7.1% | -27.5% | ||
| Q3 24 | 5.2% | 17.8% | ||
| Q2 24 | 9.4% | -3.0% | ||
| Q1 24 | 10.0% | 8.2% |
| Q4 25 | 0.5% | 12.1% | ||
| Q3 25 | 2.7% | 14.7% | ||
| Q2 25 | 1.9% | 10.2% | ||
| Q1 25 | 1.3% | 16.8% | ||
| Q4 24 | 1.3% | 13.1% | ||
| Q3 24 | 3.2% | 13.8% | ||
| Q2 24 | 3.2% | 10.9% | ||
| Q1 24 | 3.3% | 13.0% |
| Q4 25 | 1.10× | — | ||
| Q3 25 | 1.66× | — | ||
| Q2 25 | 8.87× | — | ||
| Q1 25 | 2.23× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 1.00× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ANIP
| Sales Of Cortrophin Gel | $111.4M | 45% |
| Sales Of Generic Pharmaceutical Products | $100.8M | 41% |
| Sales Of ILUVIEN And YUTIQ | $19.8M | 8% |
| Sales Of Established Brands | $12.3M | 5% |
| Unapproved Products | $6.5M | 3% |
| Sales Of Royalties And Other Pharmaceutical Services | $2.7M | 1% |
CTEV
Segment breakdown not available.
